RARE - Ultragenyx Pharmaceutical Inc.
21.46
-0.340 -1.584%
Share volume: 2,426,438
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$21.80
-0.34
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-03-2024 | 08-02-2024 | 11-05-2024 | 02-19-2025 | 05-06-2025 | 08-05-2025 | 11-04-2025 | 02-18-2026 | |
| Assets | |||||||||
| Total Assets | 1.307 B | 1.618 B | 1.538 B | 1.503 B | 1.312 B | 1.306 B | 1.190 B | 1.532 B | |
| Current Assets | 595.967 M | 964.640 M | 799.608 M | 817.123 M | 699.155 M | 719.788 M | 643.206 M | 951.000 M | |
| Inventories | 35.907 M | 40.137 M | 43.334 M | 45.007 M | 46.031 M | 46.498 M | 52.200 M | 52.000 M | |
| Other Current Assets | 47.727 M | 54.700 M | 41.365 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 47.727 M | 54.700 M | 470.989 M | 436.296 M | 367.385 M | 311.279 M | 222.738 M | 259.000 M | |
| Total Receivables | 100.253 M | 105.982 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 412.080 M | 763.821 M | 150.619 M | 173.729 M | 127.055 M | 176.306 M | 202.510 M | 421.000 M | |
| Total Non-current Assets | 711.113 M | 653.797 M | 203.086 M | 135.004 M | 68.563 M | 51.454 M | 22.067 M | 57.000 M | |
| Property Plant Equipment | 285.111 M | 278.707 M | 272.448 M | 265.929 M | 260.906 M | 255.763 M | 249.961 M | 244.000 M | |
| Other Assets | 59.970 M | 53.772 M | 466.307 M | 420.404 M | 351.866 M | 330.714 M | 297.278 M | 337.000 M | |
| Intangible Assets | 165.045 M | 166.243 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 44.406 M | 44.406 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.307 B | 1.618 B | 1.538 B | 1.503 B | 1.312 B | 1.306 B | 1.190 B | 1.532 B | |
| Total liabilities | 1.167 B | 1.186 B | 1.185 B | 1.241 B | 1.161 B | 1.148 B | 1.174 B | 1.605 B | |
| Total current liabilities | 245.575 M | 272.866 M | 285.008 M | 344.153 M | 291.668 M | 293.244 M | 340.022 M | 384.000 M | |
| Accounts Payable | 40.972 M | 59.807 M | 35.990 M | 38.756 M | 47.450 M | 34.242 M | 40.573 M | 31.000 M | |
| Other liabilities | 863.204 M | 857.354 M | 869.470 M | 866.948 M | 838.955 M | 824.677 M | 804.206 M | 1.191 B | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 863.204 M | 857.354 M | 869.470 M | 866.948 M | 838.955 M | 824.677 M | 804.206 M | 1.191 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 140.264 M | 432.418 M | 346.827 M | 255.297 M | 144.246 M | 151.286 M | 9.159 M | -80.000 M | |
| Common stock | 84.286 M | 86.581 M | 4.169 B | 4.213 B | 4.253 B | 4.374 B | 4.412 B | 4.451 B | |
| Retained earnings | -3.558 B | -3.690 B | -3.823 B | -3.957 B | -4.108 B | -4.223 B | -4.403 B | -4.532 B |